Clinical Research Directory

Inclusion Criteria: * Patients with diagnoses of HCC according to European Association for the Study of Liver disease (EASL) criteria for diagnosis (See Appendix 1). Regional lymphadenopathy will be allowed. * Any virus status accepted (e.g. Hepatitis C etc.) * Any prior liver treatment * Patients within unresectable HCC * At least 18 years old * ECOG performance status 0 or 1 * Radiographically measurable disease per mRECIST 1.1 * Meets standard of care to undergo embolization Exclusion Criteria: * Women who are pregnant or lactating * Documented hypersensitivity to bumetanide or sulfonamides * Patients with resectable HCC * High risk for post-embolization hepatic failure: °Child's C cirrhosis °\> 80% liver involvement by tumor * Contraindication to angiography/embolization including: * Patients cannot receive contrast: * Severe allergic reaction to contrast despite premedication * Poor renal function not on dialysis * Other, based on judgment of the investigator * ECOG score 2 * Main portal vein tumor thrombus * BCLC D = patients with distant metastasis